Faculty Opinions recommendation of Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718373656.793494835 ◽

2014 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Versus Treatment

Download Full-text

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70178-0 ◽

2014 ◽

Vol 15 (7) ◽

pp. 689-699 ◽

Cited By ~ 350

Author(s):

Ian E Krop ◽

Sung-Bae Kim ◽

Antonio González-Martín ◽

Patricia M LoRusso ◽

Jean-Marc Ferrero ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Versus Treatment

Download Full-text

Relationship between tumor biomarkers (BM) and efficacy in TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician’s choice (TPC) in HER2-positive advanced breast cancer (BC) previously treated with trastuzumab and lapatinib.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.605 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 605-605 ◽

Cited By ~ 3

Author(s):

Sung-Bae Kim ◽

Hans Wildiers ◽

Ian E. Krop ◽

Abraham C.F. Leung ◽

Caroline Trudeau ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Tumor Biomarkers ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase 3 ◽

Previously Treated ◽

Versus Treatment

Download Full-text

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30312-1 ◽

2017 ◽

Vol 18 (6) ◽

pp. 732-742 ◽

Cited By ~ 169

Author(s):

Véronique Diéras ◽

David Miles ◽

Sunil Verma ◽

Mark Pegram ◽

Manfred Welslau ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Advanced Breast Cancer ◽

Descriptive Analysis ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Previously Treated

Download Full-text

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30313-3 ◽

2017 ◽

Vol 18 (6) ◽

pp. 743-754 ◽

Cited By ~ 144

Author(s):

Ian E Krop ◽

Sung-Bae Kim ◽

Antonio Gonzalez Martin ◽

Patricia M LoRusso ◽

Jean-Marc Ferrero ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Previously Treated ◽

Versus Treatment

Download Full-text

Abstract OT1-04-04: EMERALD: A randomized, open-label, phase 3 trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine therapy for ER+/HER2- advanced breast cancer following CDK4/6 inhibitor therapy

10.1158/1538-7445.sabcs19-ot1-04-04 ◽

2020 ◽

Author(s):

Philippe Aftimos ◽

Aditya Bardia ◽

Virginia G Kaklamani ◽

Janice Lu ◽

Teeru Bihani ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Inhibitor Therapy ◽

Advanced Breast ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text

Abstract P4-14-01: Trastuzumab emtansine improves overall survival versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer: Final results from the phase 3 EMILIA study

10.1158/1538-7445.sabcs15-p4-14-01 ◽

2016 ◽

Author(s):

V Diéras ◽

D Miles ◽

S Verma ◽

M Pegram ◽

M Welslau ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase 3 ◽

Previously Treated

Download Full-text

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00332-0 ◽

2015 ◽

Vol 16 (15) ◽

pp. 1556-1568 ◽

Cited By ~ 51

Author(s):

Edith A Perez ◽

Ahmad Awada ◽

Joyce O'Shaughnessy ◽

Hope S Rugo ◽

Chris Twelves ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Open Label ◽

Phase 3 ◽

Multicentre Phase ◽

Previously Treated ◽

Etirinotecan Pegol ◽

Versus Treatment

Download Full-text

Faculty Opinions recommendation of Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718355395.793494247 ◽

2014 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Her2 Positive ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Abstract P1-18-05: Subcutaneous trastuzumab and hyaluronidase-oysk with intravenous pertuzumab and docetaxel in HER2-positive advanced breast cancer: Final analysis of the phase IIIb, multicenter, open-label, single-arm MetaPHER study

10.1158/1538-7445.sabcs19-p1-18-05 ◽

2020 ◽

Author(s):

Sherko Kümmel ◽

Carlo A Tondini ◽

Jacinta Abraham ◽

Zbigniew Nowecki ◽

Bartosz Itrych ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Final Analysis ◽

Advanced Breast ◽

Her2 Positive ◽

Open Label ◽

Phase Iiib

Download Full-text

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70138-x ◽

2014 ◽

Vol 15 (6) ◽

pp. 580-591 ◽

Cited By ~ 281

Author(s):

Fabrice André ◽

Ruth O'Regan ◽

Mustafa Ozguroglu ◽

Masakazu Toi ◽

Binghe Xu ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Her2 Positive ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text